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Abstract
Background: Late-stage chronic kidney disease (LS-CKD) can be defined by glomerular filtration rate (GFR) 0–30 mL/min. It is
a period of risk for medication discrepancies because of frequent hospitalizations, fragmented medical care, inadequate
communication and polypharmacy. In this study, we sought to characterize medication discrepancies in LS-CKD.
Methods: We analyzed all patients enrolled in Northwell Health’s Healthy Transitions in LS-CKD program. All patients had
estimated GFR 0–30 mL/min, not on dialysis. Medications were reviewed by a nurse at a home visit. Patients’ medication
usage and practice were compared with nephrologists’ medication lists, and discrepancies were characterized. Patients
were categorized as having either no discrepancies or one or more. Associations between patient characteristics and
number of medication discrepancies were evaluated by chi-square or Fisher’s exact test for categorical variables, and
two-sample t-test or Wilcoxon text for continuous variables.
Results: Seven hundred and thirteen patients with a median age of 70 (interquartile range 58–79) years were studied.
There were 392 patients (55.0% of the study population) with at least one medication discrepancy. The therapeutic classes
of medications with most frequently occurring medication discrepancies were cardiovascular, vitamins, bone and mineral
disease agents, diuretics, analgesics and diabetes medications. In multivariable analysis, factors associated with higher
risk of discrepancies were congestive heart failure [odds ratio (OR) 2.13; 95% confidence interval (CI) 1.44–3.16; P¼0.0002]
and number of medications (OR 1.29; 95% CI 1.21–1.37; P<0.0001).
Conclusions: Medication discrepancies are common in LS-CKD, affect the majority of patients and include high-risk
medication classes. Congestive heart failure and total number of medications are independently associated with
greater risk for multiple drug discrepancies. The frequency of medication discrepancies indicates a need for great care
in medication management of these patients.
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Introduction
Medication discrepancies can be defined as a mismatch
between a treating physician’s understanding of patients’ cur-
rent medications (including dose and frequency) and the actual
medications that the patient takes. Discrepancies have the
potential to impair the effectiveness and safety of medication
treatment. Ideally, the physician conducts a medication recon-
ciliation with the patient and educates patients about medica-
tions. In addition, the physician should maintain good
communication with other medical providers regarding medi-
cation changes. In actual practice, however, medication discrep-
ancies are frequent, occurring in 34–95% of patients at the
time of admission for acute hospitalizations or psychiatric clin-
ics [1, 2]. When discrepancies occur there may be failure to rec-
ognize symptoms and signs as medication side effects and
increased risk for adverse events [3]. A systematic review of
acute hospitalizations found that 11–59% of medication discrep-
ancies were clinically important and 39% had potential to cause
moderate-to-severe patient harm [1].
To date there have been no studies of medication discrepan-
cies in late-stage chronic kidney disease (LS-CKD). LS-CKD can
be defined as CKD Stages 4–5, prior to the initiation of renal
replacement therapy. There are several reasons to suspect that
medication discrepancies may be common in LS-CKD. Patients
often take multiple medications, reaching a mean of 11.8 by the
time of dialysis need [4]. Polypharmacy and conflicting dosing
schedules are never easy for patients to manage. This is prob-
ably more true in LS-CKD, where patients are usually older and
have comorbidities including cognitive decline. In addition,
patients with LS-CKD often have multiple different physicians
involved in their care. The result can sometimes be care frag-
mentation with confusion created by numerous drug and dos-
ing changes. Frequent hospitalizations among patients with LS-
CKD result in medication and dose changes, often without
adequate reconciliation and communication among providers
at hospital discharge. In general, communication problems are
a recurring theme throughout the care system, contributing to
medication risk.
Since 2012, we have operated the Healthy Transitions care
management program for patients with LS-CKD. Nephrologist
treatment is supplemented by nursing care management serv-
ices and advanced informatics. All program patients have an
initial home visit, which offers a unique opportunity for medi-
cation review. The visit occurs as the initial program contact, so
the medication reviews are free from any interventional effect.
At the visit, the patient and key caregivers show the bottles of
medications being used and explain how many pills are taken
and how frequently. Because this occurs in the patient’s home,
with the actual drugs consumed, it is a rigorous form of medica-
tion review. In this analysis, we sought to utilize this uniquely
clear view of medication use to better understand and charac-
terize the frequency, type and risk factors for medication dis-
crepancies in LS-CKD. We are aware of no previous studies of
this subject in CKD and studies in other populations have often
relied on health record reviews rather than direct patient inter-
views [5, 6].
Materials and methods
Patient population
The Healthy Transitions in Late Stage Kidney Disease program
began operation in October 2012. The program provides nursing
care management services to patients with LS-CKD, in an effort
to facilitate care processes and improve preparation for end-
stage kidney disease (all such patients were eligible for partici-
pation in the program). The program includes patients with
CKD Stages 4–5 defined as estimated glomerular filtration rate
(eGFR) 0–30 mL/min, and excludes patients (i) on dialysis and
(ii) with significant cognitive impairment, defined as need for
assistance with activities of daily living. The program began as
a pilot, entered a full implementation phase and subsequently
had an imbedded randomized controlled trial (RCT) [7] and a
3-year period of funding by Centers for Medicare and Medicaid
Innovation program Health Care Innovations Award.
All patients enrolled throughout all program phases from
October 2012 to December 2016 were included in the current
analysis except for patients from the RCT control group. The
justification for inclusion of all of these program phase patients
is that all had exactly the same initial home visit with medica-
tion review conducted prior to any other interventions. The pro-
gram functions and patients were enrolled, from Nassau,
Suffolk, Queens, Kings and New York counties of New York
State. There have been seven different participating nephrology
groups. Three of the offices were private practices, four were
academic nephrology practices. There was no standardized
method for medication history-taking among the nephrologists.
Medication review
Medication discrepancies were defined from the perspective of
the nephrologist. Most patients had a recent visit with the
nephrologist at the time of program enrollment. After enroll-
ment, a home visit was conducted by a program nurse. The
nephrologist’s medication list was printed from the electronic
health record (EHR) prior to the home visit. All program neph-
rologists’ EHRs prompt for medication reconciliation at all
patient visits.
Medication reviews were all conducted by one of the pro-
gram’s registered nurses. All took place during an initial home
visit that occurred prior to any other program interventions.
The purpose of the home visit is to begin to build a trusting rela-
tionship, to assess the patient’s knowledge regarding their kid-
ney disease, to initiate education regarding modality options for
renal replacement therapy and diet and most relevant to the
current analysis, to conduct a complete medication review.
The medication portion of the visit begins with the nurse
asking the patient and key care giver where in the home medi-
cations are kept, and how the patient carries medications if
needed during the day. Next, the patient was asked to remove
their currently used medication jars from their medicine cabi-
net or other storage area. In many cases, the nurse helped the
patient with this task. Each medication jar was reviewed indi-
vidually with attention to accuracy. The patient was questioned
on (i) if the medication was currently being taken, (ii) how many
pills, (iii) how many times a day and (iv) were there any other
medications, including over-the-counter agents, herbals or vita-
mins, that the patient took. The patient was questioned on
other medications that were on the nephrologist’s medication
list but that the patient was not taking at that time. For any dif-
ference between the nephrologist’s list of medications and the
patient’s actual medication consumption, a discrepancy and its
characteristics were recorded. Although all patients had subse-
quent medication reviews as part of the program, only the base-
line review was included in the current analysis to avoid
potential bias introduced by program interventions.
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Statistical analyses
Baseline patient demographics (age, gender, race, ethnicity,
hypertension, diabetes, congestive heart failure, insurance type,
smoking status and eGFR) were described using categorical or
continuous variables as appropriate. In the entire patient
cohort, the frequency, proportion and type of medication dis-
crepancy was described. Categorization of medication discrep-
ancy type was determined a priori, and included therapeutic
class, and any difference between the nephrologist’s list of
medications and the patient’s actual medication consumption
(i.e. patient taking medication not on nephrologist’s list, patient
not taking medication on nephrologist’s list, different dose and/
or different frequency, drug discontinued and patient taking,
drug discontinued and still on nephrologist’s list or patient not
taking medication as instructed).
To evaluate patient characteristics associated with risk for
multiple medication discrepancies, we first divided patients
into two categories, one with no medication discrepancies and
one with one or more discrepancies. We decided on categoriza-
tion prior to any inspection of results by category. The variables
chosen for study were based on availability and then on those
with potential causal pathways. In an initial univariable analy-
sis, we used chi-square or Fisher’s exact test as appropriate for
categorical variables, and two-sample t-test or Wilcoxon text as
appropriate for continuous variables, to evaluate the associa-
tion of each patient characteristic with the outcome of number
of medication discrepancies (no discrepancies versus one or
more). In subsequent multivariable logistic regression analysis,
factors that were found statistically significant in the univari-
able analysis plus age and gender were taken as the candidate
variables for the final model. We conducted all analyses using
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 713 patients were reviewed who were enrolled from
October 2012 to December 2016. In the entire cohort, the median
age was 70 [interquartile range (IQR) 58–79] years, 56.5% were
men, 24.4% were black, 60.9% were white, 9% were Hispanic,
51.1% were diabetic and 92.8% had hypertension. Patient char-
acteristics are displayed in Table 1. The distribution of eGFR
was <10 mL/min, 7.3%; 10–15 mL/min, 26.3%; 15.1–20 mL/min,
25%; > 20 mL/min, 41.4%. Six patients had previously undergone
kidney transplantation. The median time from last nephrologist
medication reconciliation to nurse visit was 3 (IQR 1–6) days.
There were 392 patients (55.0% of the study population) with
at least one medication discrepancy. The total number of dis-
crepancies was 1280, and the median number of discrepancies
per patient (in patients with at least 1 discrepancy) was 2 (IQR
1–4). The distribution of discrepancies per patient is displayed
in Table 2. There were 321 patients with zero discrepancies
(45%), 125 patients with one discrepancy and 83 patients with
two discrepancies. There were 12.1% of patients with five or
more discrepancies. The most common type of discrepancies
were patients taking a medication not on nephrologist’s list
(49.1% of discrepancies), patients not taking a medication on
the nephrologist’s list (22.7%), different dose (18.4%) and differ-
ent frequency (5%) (Figure 1). The therapeutic medication
classes with the greatest number of discrepancies were cardio-
vascular (15.5% of discrepancies), vitamins (11.0%), bone and
mineral disease agents (8.9%), diuretics (7.0%), analgesics (6.7%)
and diabetes medications (5.0%) (Figure 2). The types of discrep-
ancies were similar for different drug classes. Among cardiovas-
cular drugs, the subcategories with the greatest number of
discrepancies were renin angiotensin aldosterone system inhib-
itors (66% of cardiovascular discrepancies) and beta blockers
(24%).
When assessing the outcome of multiple medication dis-
crepancies, there were 321 patients with no discrepancies, and
392 patients with one or more discrepancies. In a univariable
analysis, the following patient characteristics were found to be
associated with medication discrepancies (P< 0.05): congestive
Table 1. Patient characteristics
Characteristic n (% or SD)
Mean age (years) 67.5 (15.9)
Male 403 (56.5)
Race
White 434 (60.9)
Black 174 (24.4)
Other or multiracial 67 (9.4)
Asian 38 (5.3)
Hispanic ethnicity 64 (9.0)
Hypertension 662 (92.8)
Diabetes 364 (51.1)
Congestive heart failure 181 (25.3)
Primary insurance type
Medicare 400 (56.1)
Private 239 (33.5)
Medicaid 67 (9.4)
No insurance 7 (1)
Active smoker
Yes 41 (5.8)
No 666 (93.4)
Not specified 6 (0.8)
Mean eGFR (mL/min) 18.666.4
eGFR category (mL/min)
<10 52 (7.3)
10–15 188 (26.4)
15.1–20 178 (25)
>20 295 (41.4)
Mean number of medications 8.1 (3.4)
Table 2. Frequency distribution of number of medication discrepan-
cies per patient
Medication discrepancies per patient Number Percentage
0 321 45.0
1 125 17.5
2 83 11.6
3 57 8.0
4 41 5.8
5 19 2.7
6 24 3.4
7 14 2.0
8 4 0.6
9 5 0.7
10 8 1.1
11 3 0.4
12 3 0.4
13 1 0.1
14 2 0.3
15 1 0.1
16 1 0.1
17 0 0.0
18 1 0.1
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heart failure, white race, hypertension and number of medica-
tions taken (Table 3). In subsequent multivariable logistic
regression analysis, factors that were found statistically signifi-
cant in the univariable analysis plus age and gender were taken
as the candidate variables for the final model. After backward
variable selection, factors in the final model independently
associated with higher risk of one or more medication discrep-
ancies compared with zero discrepancy were congestive heart
failure [odds ratio (OR) 2.13; 95% confidence interval (CI) 1.44–
3.16; P ¼ 0.0002] and number of medications (OR 1.29; 95% CI
1.21–1.37; P< 0.0001) (Table 4).
Discussion
We found that more than half of patients with LS-CKD had at
least one discrepancy between the nephrologist’s medication
record and the medications actually being consumed.
Approximately one-third of patients had two or more discrep-
ancies. Most discrepancies were related to medications being
taken that were not on the nephrologist’s list, medications on
the nephrologist’s list that were not being taken, and dose and
frequency differences.
Effective medication management is achieved by optimizing
the benefits and reducing risks of treatment. Ongoing medica-
tion review and reconciliation by the provider is essential for
longitudinal maintenance of medication safety. When discrep-
ancies develop between the medications that the provider
intends for the patient to be taking and those actually being
used, there is increased risk for loss of efficacy or adverse
events. Discrepancies can be highly relevant, with a recent
study finding that in intensive care units, 17.1% of discrepancies
were serious or potentially life-threatening [8].
In the treatment of patients with LS-CKD, the medication
management process is fraught with polypharmacy, extensive
comorbidity and altered medication pharmacology due to
reduced renal function, fragmented medical care and frequent
hospitalizations. The nephrologist plays a key and often princi-
pal role in maintenance of medication safety in these patients.
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Fig. 2. Frequency of medication discrepancies by therapeutic class.
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Our finding of a high rate of medication discrepancies signifies
an important gap in performance and opportunity for improve-
ment in LS-CKD. The fact that more than one-third of patients
had two or more discrepancies is a strong indicator of the mag-
nitude of the problem.
It is concerning that cardiovascular medications were the
most commonly discrepant class of medication and diuretics
the fourth most common, because of the hemodynamic and
metabolic effects of these agents. This aligns with the finding
that congestive heart failure as comorbidity was a key inde-
pendent predictor of multiple discrepancies. It is likely that con-
cordant cardiac disease creates important vulnerabilities in
medication management in LS-CKD. The diseases complicate
and confound treatment of each other. Medications such as
renin angiotensin aldosterone system inhibitors and diuretics
are adjusted frequently in response to cardiac, renal or electro-
lyte disturbances. When the medications are changed, commu-
nication between physicians may often be suboptimal. This
complex, chaotic setting is fertile ground for medication dis-
crepancies and complications.
We also found that the number of medications that patients
were taking was associated with greater risk for discrepancies.
This is an intuitive finding and consistent with existing knowl-
edge [9]. In LS-CKD, patients take a large number of medications
and it is wise to review ongoing need for all chronic medications.
Reduction in medication discrepancies in LS-CKD requires a
more intensive approach to medication reconciliation. Sharing of
medication information between healthcare providers and accu-
rate is a prerequisite. Incorporation of pharmacy information on
medication fill histories into EHRs holds great promise [10]. Ideally,
the physician’s medication record should reflect the time of the
last patient visit or other communication, but annotated with sub-
sequent activity from other providers and pharmacies. Improved
patient education is important as well, as it is probable that better
understanding of medications and their purpose would enhance
patient adherence and limit errors. Polypharmacy is certainly an
issue as well. The mean number of medications taken by LS-CKD
patients is substantial. Elimination of unnecessary medications
should be an ongoing effort to improve patient safety.
Strengths of our study include the large numbers of patients
in different types of practice settings. In addition the determina-
tion of medication discrepancies was by a highly rigorous
approach with home visits and review of actual medication bot-
tles and usage descriptions by the patient and key caregivers.
Limitations include the geographically limited region covered,
the metropolitan New York counties of Nassau, Suffolk,
Queens, Kings and Manhattan. In addition, there was underre-
presentation of individuals with Hispanic ethnicity. Hispanic
patients made up only 9% of the study population, compared
with 17% of the US population. The dataset had a low propor-
tion of missing data in that 15% of discrepancies were accom-
panied by insufficient documentation of the specific involved
medication. In addition, we were unable to determine which
discrepancies might create a higher level of risk to patients as
no available classification scheme is reliable. Additionally, we
were not able to identify potential intentional discrepancies, for
example, if a second physician had changed a medication.
Finally, our dataset also did not allow for determination of the
underlying reasons for unintentional medication discrepancies.
In conclusion, we found a high rate of medication discrepan-
cies in LS-CKD. There is a need to better understand the subject
to help improve medication management and reduce risk for
medication errors. Future research efforts should focus on
whether discrepancies relate to patient outcomes and on causa-
tive factors for medication discrepancies.
Funding
Part of this work was funded by the Centers for Medicare
and Medicaid Innovation Program.
Table 3. Univariate association of patient characteristics and num-
ber of medication discrepancies
Number of medication
discrepancies
Patient characteristics
Zero
discrepancies
(n¼ 321)
1 discrepancy
(n¼ 392) P-value
Mean number of
discrepancies (SD)
0 3.3 (2.8) NA
Mean (6SD) age (years) 68.0615.8 67.3616.1 0.40
Gender, n (%) 0.15
Male 172 (42.7) 231 (57.3)
Female 149 (48.1) 161 (51.9)
Race, n (%) 0.03
White 177 (40.8) 257 (59.2)
Black 89 (51.2) 85 (48.9)
Other or multiracial 33 (49.3) 34 (50.8)
Asian 22 (57.9) 16 (42.1)
Hispanic ethnicity, n (%) 0.27
Yes 33 (51.6) 31 (48.4)
No 288 (44.4) 361 (55.6)
Hypertension, n (%) 0.01
Yes 289 (43.7) 373 (56.3)
No 32 (62.8) 19 (37.2)
Diabetes mellitus, n (%) 0.90
Yes 163 (44.8) 201 (55.2)
No 158 (45.3) 191 (54.7)
Congestive heart
failure, n (%)
0.0004
Yes 61 (33.7) 120 (66.3)
No 260 (48.9) 272 (51.1)
Current smoker, n (%) 0.82
Yes 20 (48.8) 21 (51.2)
No 298 (44.7) 368 (55.3)
Not specified 3 (50.0) 3 (50.0)
Insurance status, n (%) 0.23
Medicaid 37 (55.2) 30 (44.8)
Medicare 180 (45.0) 220 (55.0)
No insurance 4 (57.1) 3 (42.9)
Private 100 (41.8) 139 (58.2)
Mean (6SD) eGFR (mL/min) 19.166.6 18.366.2 0.08
Mean (6SD) number of
medications
6.862.3 9.263.8 <0.0001
Table 4. Multivariable analysis for medication discrepancy (logistic
regression)
Multivariable analysis for medication discrepancy
Variables
Odds ratio
(95% confidence interval) P-value
CHF (yes versus no) 2.13 (1.44–3.16) 0.0002
Number of medications 1.29 (1.21–1.37) <0.0001
CHF, congestive heart failure.
Medication discrepancies in LS-CKD | 511
Conflict of interest statement
None declared.
References
1. Tam VC, Knowles SR, Cornish PL et al. Frequency, type and
clinical importance of medication history errors at admis-
sion to hospital: a systematic review. CMAJ 2005; 173:
510–515
2. Prins MC, Drenth-van Maanen AC, Kok RM et al. Use of a
structured medication history to establish medication use at
admission to an old age psychiatric clinic: a prospective
observational study. CNS Drugs 2013; 27: 963–969
3. Simoons M, Mulder H, Risselada AJ et al. Medication discrep-
ancies at outpatient departments for mood and anxiety dis-
orders in the Netherlands: risks and clinical relevance. J Clin
Psychiatry 2016; 77: 1511–1518
4. Manley HJ, Cannella CA, Bailie GR et al. Medication-related
problems in ambulatory hemodialysis patients: a pooled
analysis. Am J Kidney Dis 2005; 46: 669–680
5. Patel CH, Zimmerman KM, Fonda JR et al. Medication com-
plexity, medication number, and their relationships to med-
ication discrepancies. Ann Pharmacother 2016; 50: 534–540
6. Hale J, Neal EB, Myers A et al. Medication discrepancies and
associated risk factors identified in home health patients.
Home Healthcare Now 2015; 33: 493–499
7. Fishbane S, Agoritsas S, Bellucci A et al. Augmented nurse
care management in CKD stages 4 to 5: a randomized trial.
Am J Kidney Dis 2017; 70: 498–505
8. Wills BM, Darko W, Seabury R et al. Pharmacy impact on
medication reconciliation in the medical intensive care unit.
J Res Pharm Pract 2016; 5: 142–145
9. Hias J, Van der Linden L, Spriet I et al. Predictors for uninten-
tional medication reconciliation discrepancies in preadmis-
sion medication: a systematic review. Eur J Clin Pharmacol
2017; 73: 1355–1377
10. Pevnick JM, Palmer KA, Shane R et al. Potential benefit of
electronic pharmacy claims data to prevent medication his-
tory errors and resultant inpatient order errors. J Am Med
Inform Assoc 2016; 23: 942–950
512 | J. Ibrahim et al.
